Show simple item record

dc.contributor.authorGuckenberger, M
dc.contributor.authorLievens, Y
dc.contributor.authorBouma, AB
dc.contributor.authorCollette, L
dc.contributor.authorDekker, A
dc.contributor.authordeSouza, NM
dc.contributor.authorDingemans, A-MC
dc.contributor.authorFournier, B
dc.contributor.authorHurkmans, C
dc.contributor.authorLecouvet, FE
dc.contributor.authorMeattini, I
dc.contributor.authorMéndez Romero, A
dc.contributor.authorRicardi, U
dc.contributor.authorRussell, NS
dc.contributor.authorSchanne, DH
dc.contributor.authorScorsetti, M
dc.contributor.authorTombal, B
dc.contributor.authorVerellen, D
dc.contributor.authorVerfaillie, C
dc.contributor.authorOst, P
dc.date.accessioned2020-04-09T10:32:14Z
dc.date.issued2020-01-01
dc.identifier.citationThe Lancet. Oncology, 2020, 21 (1), pp. e18 - e28
dc.identifier.issn1470-2045
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3585
dc.identifier.eissn1474-5488
dc.identifier.doi10.1016/s1470-2045(19)30718-1
dc.description.abstractOligometastatic disease has been proposed as an intermediate state between localised and systemically metastasised disease. In the absence of randomised phase 3 trials, early clinical studies show improved survival when radical local therapy is added to standard systemic therapy for oligometastatic disease. However, since no biomarker for the identification of patients with true oligometastatic disease is clinically available, the diagnosis of oligometastatic disease is based solely on imaging findings. A small number of metastases on imaging could represent different clinical scenarios, which are associated with different prognoses and might require different treatment strategies. 20 international experts including 19 members of the European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer OligoCare project developed a comprehensive system for characterisation and classification of oligometastatic disease. We first did a systematic review of the literature to identify inclusion and exclusion criteria of prospective interventional oligometastatic disease clinical trials. Next, we used a Delphi consensus process to select a total of 17 oligometastatic disease characterisation factors that should be assessed in all patients treated with radical local therapy for oligometastatic disease, both within and outside of clinical trials. Using a second round of the Delphi method, we established a decision tree for oligometastatic disease classification together with a nomenclature. We agreed oligometastatic disease as the overall umbrella term. A history of polymetastatic disease before diagnosis of oligometastatic disease was used as the criterion to differentiate between induced oligometastatic disease (previous history of polymetastatic disease) and genuine oligometastatic disease (no history of polymetastatic disease). We further subclassified genuine oligometastatic disease into repeat oligometastatic disease (previous history of oligometastatic disease) and de-novo oligometastatic disease (first time diagnosis of oligometastatic disease). In de-novo oligometastatic disease, we differentiated between synchronous and metachronous oligometastatic disease. We did a final subclassification into oligorecurrence, oligoprogression, and oligopersistence, considering whether oligometastatic disease is diagnosed during a treatment-free interval or during active systemic therapy and whether or not an oligometastatic lesion is progressing on current imaging. This oligometastatic disease classification and nomenclature needs to be prospectively evaluated by the OligoCare study.
dc.formatPrint
dc.format.extente18 - e28
dc.languageeng
dc.language.isoeng
dc.publisherELSEVIER SCIENCE INC
dc.rights.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectNeoplasm Metastasis
dc.subjectConsensus
dc.subjectMedical Oncology
dc.subjectPractice Guidelines as Topic
dc.titleCharacterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation.
dc.typeJournal Article
dcterms.dateAccepted2019-10-15
rioxxterms.versionofrecord10.1016/s1470-2045(19)30718-1
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
rioxxterms.licenseref.startdate2020-01
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfThe Lancet. Oncology
pubs.issue1
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Magnetic Resonance
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Magnetic Resonance
pubs.publication-statusPublished
pubs.volume21
pubs.embargo.termsNot known
icr.researchteamMagnetic Resonance
dc.contributor.icrauthordeSouza, Nandita


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record